Addition of pembrolizumab to chemotherapy extends survival in advanced lung cancer

10:13 EDT 4 Jun 2018 | The Pharmaceutical Journal

Introducing first-line immunotherapy could benefit long-term outcomes in advanced non-small-cell lung cancer (NSCLC), a study has revealed.

More From BioPortfolio on "Addition of pembrolizumab to chemotherapy extends survival in advanced lung cancer"